Thelansis’s "Pulmonary Arterial Hypertension (PAH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pulmonary Arterial Hypertension treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary arteries that raises vascular resistance and strains the right ventricle. Symptoms include exertional breathlessness, fatigue, dizziness, or syncope; advanced disease can cause right-sided heart failure. PAH can be idiopathic, heritable, or associated with connective-tissue disease. Treatment is guided by risk assessment and may combine endothelin-receptor antagonists, nitric oxide pathway drugs, and prostacyclin therapies. Sotatercept, an activin-signaling inhibitor, adds a fourth treatment pathway and is approved in the United States for adults to improve exercise capacity, functional class, and clinical outcomes. 2026 ERS guidance recommends considering add-on sotatercept for patients at intermediate-low, intermediate-high, or high risk despite PAH therapy, with specialist monitoring. Despite progress, disease progression and treatment-related risks persist, sustaining research into long-term outcomes.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Pulmonary Arterial Hypertension (PAH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Pulmonary Arterial Hypertension (PAH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.